AI Article Synopsis
- The XEN glaucoma implant is a new device approved for treating glaucoma, designed for minimally invasive procedures.
- A 45-year-old female with primary open-angle glaucoma had the XEN implant placed in both eyes after previous treatments failed.
- The implant initially controlled her intraocular pressure for 4 months, but a complication arose when the implant moved to the anterior chamber, requiring additional treatment to manage her eye pressure.
Article Abstract
Background: XEN glaucoma implant (XEN gel stent, Aquesys, Inc) is a new minimally invasive device approved for the treatment of glaucoma.
Case Presentation: A 45 year old female was being followed and treated for primary open angle glaucoma in our tertiary referral center. Due to failure of medical treatment in controlling the glaucoma, surgery was offered to the patient. The XEN 45 μ-fistula implant was successfully placed in both eyes and adequate intraocular pressure control was achieved for 4 months. The left eye pressure then increased and the XEN implant was found in the anterior chamber. Topical intraocular pressure lowering therapy had to be re-initiated to achieve adequate pressure control.
Conclusion: We describe a new potential complication of the XEN glaucoma implant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568059 | PMC |
| http://dx.doi.org/10.1186/s12886-017-0540-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!